AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00324467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesna (IV)
Description: R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5000 mg/m\^2 (total dose per cycle) Administration: In 3 equally divided doses IV infusion days 1,2,3 (with ifosfamide) over 2 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
Study NCT00324467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesna (oral)
Description: R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 2 g Administration: PO 2h and 4h after ifosfamide infusion on days 1,2,3 Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
Study NCT00324467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5 x (25+CrCl\*) (maximum dose 800 mg) Administration: IV infusion day 1 over 1 hour Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)~\*Carboplatin is dose via the Calvert formula with an AUC of 5, maximum dose 800 mg per cycle.~Estimate Creatinine Clearance (CrCl)
Study NCT00324467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 100 mg/m\^2 Administration: IV infusion day 1,2,3 over 30 minutes Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
Study NCT00324467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 375 mg/m\^2 Administration: IV infusion day 1 (or day 2 or day 3) over 90 minutes-8 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
Study NCT00324467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Premedication for R-ICE Dose: 8 mg Route: PO Schedule: 15 min pre-chemotherapy daily
Study NCT00324467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Premedication for R-ICE Dose: 8 mg Route: PO Schedule: 15 min pre-chemotherapy daily
Study NCT00324467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: Premedication for R-ICE Dose: 50 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
Study NCT00324467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Premedication for R-ICE Dose: 650 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
Study NCT00324467 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PET Scan
Description: Investigations: 18F-FDG-PET scan Timing: After 4 cycles of R-CHOP (days 21-28) and after 4 cycles of R-ICE (days 28-35)
Study NCT01516944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin
Description: Tegafur，Gimeracil and Oteracil Potassium Capsules 80 mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for six cycles postoperation
Study NCT01516944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin
Description: Tegafur，Gimeracil and Oteracil Potassium Capsules 80mg/㎡ ,D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for two cycles preoperation, Tegafur，Gimeracil and Oteracil Potassium Capsules ,80 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for six cycles postoperation
Study NCT01516944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin; Capecitabine
Description: Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for two cycle pre-operation, Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/m2 D1 q3wk for six cycles postoperation
Study NCT01666665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Sugar pill up to 3 times per day for 12 months
Study NCT01699958 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-solving intervention
Description: Participants will receive 2 individual sessions teaching and reviewing problem-solving skills.
Study NCT04653025 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant placement
Description: After tooth extraction implants were placed either immediate or delayed approach
Study NCT01228799 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trabeculectomy
Description: trabeculectomy with mitomycin C 0.2mg/ml
Study NCT01228799 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Canaloplasty
Description: Canaloplasty with implant of suture
Study NCT01659125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OCFighter
Description: OCFighter™ s an interactive, internet guided self-help (GSH) treatment program for obsessive-compulsive disorder (OCD). It uses the evidence based approach known as Cognitive Behavioral Therapy (CBT) and was adapted from the previously validated BT STEPS program for OCD. The program teaches the best practice CBT technique to help with OCD called exposure with ritual prevention (ERP).
Study NCT03066258 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-314
Description: RGX-314 is a recombinant adeno-associated virus (AAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein
Study NCT01480245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2402968
Description: 6mg/kg/week
Study NCT00621270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCI-540
Description: BCI-540 80 mg once (q.d.) or three times (t.i.d.) a day versus placebo
Study NCT00621270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BCI-540
Description: BCI-540 80 mg once (q.d.) or three times (t.i.d.) a day versus placebo
Study NCT00367302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine
Description: maintenance
Study NCT00367302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methadone
Description: maintenance
Study NCT05123378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liberia National Community Health Assistant Program
Description: Through the National Community Health Assistant Program (NCHAP), members of remote communities select Community Health Assistants (CHAs). Once selected, CHAs are trained to deliver direct services which include; treatment of diarrhea, ARI, and malaria following Integrated Community Case Management (iCCM) protocols, referrals for patients with clinical danger signs, family planning for women of childbearing age and birth preparedness and education for pregnant women. CHAs are also trained to deliver indirect services which include; health education, active surveillance, referral for mental health and other special conditions for all age groups. Since 2020 COVID-education has also been included in the CHAs work.
Study NCT03578393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Educational Program
Description: The study group, in addition to providing the usual information about the anaesthetic-surgical process, will visualize an educational video through virtual reality glasses, of a maximum duration of 5 minutes. The video's explanation will be adapted according to the age ranges. Once the video is finished, if there aren't doubts, the visit will be concluded.
Study NCT02396368 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radium 223
Description: Radium Ra 223 dichloride, an alpha particle-emitting pharmaceutical, is a radiotherapeutic drug. Radium 223 is supplied as a clear, colorless, isotonic, and sterile solution to be administered intravenously with pH between 6 and 8. Each milliliter of solution contains 1,000 kBq radium-223 dichloride (27 microcurie), corresponding to 0.53 ng radium-223, at the reference date. Radium is present in the solution as a free divalent cation.Radium-223 will be administered per FDA-approved dosing (six IV injections at a dose of 50kBq/kg of body weight, administered every 4 weeks).
Study NCT01151397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg + Vitamin D + Ribavirin
Description: Peg+ Vitamin D+ Ribavirin for 3 months
Study NCT01151397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg + Ribavirin
Description: Peg+ Ribavirin for 6 months
Study NCT01701115 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Dose (20 ml) Local Anesthetic Volume for Interscalene Block
Description: Anesthetic volume:~Investigational group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 20 mL
Study NCT00919815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporin
Description: Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)
Study NCT00919815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: prednisolone 40mg daily then reducing regimen over 24 weeks
Study NCT03369483 — intervention group
Intervention type: OTHER
Intervention: Abdominal pressure assessment
Description: We will perform measurements of the abdominal pressure an urinary catheter connected with an intra-abdominal pressure device (Uno-Meter ® - Unomedical) in all patients undergoing on open-surgical procedures after mechanical ventilation withdrawal and extubation, 30 minutes and 4 hours after the application of CPAP.
Study NCT01914692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin
Description: Somatostatin is a kind of traditional medicines ,which is for the treatment of intestinal fistula，upper gastrointestinal hemorrhage.
Study NCT01192412 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention is blood pressure management approach
Description: 1) 'Less tight' control. The dBP treatment goal is 100 mmHg. For safety, if dBP is >105 mmHg, then antihypertensive medication must be started or increased in dose. For dBP \<100 mmHg, antihypertensive therapy should be decreased in dose or stopped, as appropriate. The intervention will be applied until delivery.
Study NCT01192412 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention is blood pressure management approach.
Description: 'Tight' control. The dBP treatment goal is 85 mmHg. For safety, if dBP is \<80 mmHg, then antihypertensive medication must be decreased in dose or discontinued. If dBP is >85 mmHg, then antihypertensive therapy should be started or increased in dose. The intervention will be applied until delivery.
Study NCT02836691 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EKG (electrocardiogram)
Description: Analysis of the heart rate variability with an electrocardiogram with a commercial device adapted to asthmatic patients using 12 leads, a respiratory band and a pulseoximeter.
Study NCT01933477 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MCH-focused ART services
Description: Post-partum women who are breast feeding will be retained in the antenatal clinic to receive continued MCH-focused ART services until after the end of breastfeeding and once infants' final HIV status is determined.
Study NCT01437930 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: n-3 PUFA
Description: products (sausage, bread rolls, milk beverage, wafers) enriched with Intervention a-c): n-3 rich plant oils/powder~1. linseed oil (20g/d)(PPM, Magdeburg)~2. echium oil (20g/d) (HARKE Nutrition)~3. microalgae powder(12g/d)(HARKE Nutrition)
Study NCT01231074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin dosing will be done as is typical in clinical practice. Doses will be titrated at 500mg daily for one week, to a maximum dose of 1000mg twice a day as tolerated by subject.
Study NCT00545909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bonviva/Boniva]
Description: 150mg po monthly for 6 months (+ feedback)
Study NCT00545909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibandronate [Bonviva/Boniva]
Description: 150mg po monthly for 6 months (- feedback)
Study NCT02626494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcystein
Description: n-AC will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 3 doses of n-AC over 2 consecutive days (total dose=4800mg; individual doses=2x1200mg, 1x2400mg). Subjects will take 2 first doses (à 1200mg) of n-AC 5 days after the screening assessment (one in the morning, one in the evening), and the last dose (2400mg) 1h prior to scanning, with 12 hours dosing intervals in between. Preparation and blinding of n-AC capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
Study NCT02626494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetylcystein
Description: n-AC will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 3 doses of n-AC over 2 consecutive days (total dose=4800mg; individual doses=2x1200mg, 1x2400mg). Subjects will take 2 first doses (à 1200mg) of n-AC 5 days after the screening assessment (one in the morning, one in the evening), and the last dose (2400mg) 1h prior to scanning, with 12 hours dosing intervals in between. Preparation and blinding of n-AC capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
Study NCT04263181 — intervention group
Intervention type: PROCEDURE
Intervention: Peripheral blood draw
Description: * All cohorts will have peripheral blood drawn at baseline no more than 4 days prior to the first dose of chemotherapy and must also occur before the first dose of chemotherapy~* Cohort 0 or 1 - peripheral blood draw on Day 2~* Cohorts 0, 2, 3, 4 and 5 - peripheral blood draw on Day 3~* Cohort 0 or 1 - peripheral blood draw on Day 35 (at count recovery)~* Cohorts 0, 2, 3, 4, and 5 - peripheral blood draw on Cycles 2 or 3 and 4 or 5, Day 28
Study NCT04263181 — intervention group
Intervention type: PROCEDURE
Intervention: Bone marrow aspirate
Description: * Cohort 0 or 1 - bone marrow aspirate on Day 14~* Cohort 0 or 1 - bone marrow aspirate on Day 35 (at count recovery)~* Cohorts 0, 2, 3, 4, and 5 - bone marrow aspirate on Cycles 2 or 3 and 4 or 5, Day 28
Study NCT01701115 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Dose (40 mL) Local Anesthetic Volume for Interscalene Block
Description: Anesthetic volume:~Control group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 40 mL
Study NCT01701115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose (20 mL) Local Anesthetic (Mepivacaine:Bupivacaine)
Study NCT01701115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Dose (40 mL) Local Anesthetic (Mepivacaine:Bupivacaine)
Study NCT04263181 — intervention group
Intervention type: PROCEDURE
Intervention: Buccal swab
Description: * Cohort 0 or 1 - buccal swab on Day 35 (at count recovery)~* Cohorts 0, 2, 3, 4, and 5 - buccal swab on Cycle 2 or 3 and 4 or 5, Day 28
Study NCT00826800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX and bevacizumab
Description: The patient will receive six treatments, two weeks apart. On each treatment day you will get Oxaliplatin, 5-FU,Leucovorin. On the first four treatments you will also get Bevacizumab (Avastin). These drugs are given through a Mediport. They will be given in an outpatient chemotherapy unit. Each tx will take about 4 hours. A pump for the 5-FU is worn around your waist. This drug is given over 2 days. Part II: Colon Cancer Surgery is standard practice, and is not a research procedure.Part III: Post-operative Re-Evaluation and Recovery The doctor will decide on the type of chemotherapy based on how the patient responded to the first chemotherapy. The plan will be for the patient to get 6 more doses of FOLFOX, without any further bevacizumab, unless your doctor finds a reason to do otherwise.
Study NCT04585087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intakes
Description: 6 levels of threonine intake will be provided by the protein liquid drink
Study NCT03136003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDAVP
Description: The participant will take either 1 or 2 nasal sprays of IN DDAVP (known as Octostim® in Canada). After receiving IN DDAVP, the participant will rest for 30 minutes.
Study NCT02103777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine citrate
Description: Caffeine will be given by either high dose in Arm 1 or low dose in Arm 2
Study NCT00615030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: 300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)
Study NCT00512577 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell transfusion
Description: Pre-operative red blood cell transfusion
Study NCT04237272 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pod System E-cig
Description: Participants assigned to this intervention will try to pod system e-cigarette in the lab and receive a pod system e-cigarette to use for a three week sampling period.
Study NCT04237272 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Customizable Tank E-cig
Description: Participants assigned to this intervention will try to customizable tank system e-cigarette in the lab and receive a customizable tank system e-cigarette to use for a three week
Study NCT04237272 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will not receive any e-cigarette
Study NCT04511585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Great Live and Move Challenge
Description: Physical activity program for children
Study NCT03245411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: All participants in this group will receive the standard of care intervention provided by the RN. This includes:Education in the clinic setting,Printed information about the chemotherapy drug and chemotherapy side effects. The RN will be blinded to the arm of study to which each patient is allocated.
Study NCT04566055 — intervention group
Intervention type: DEVICE
Intervention: AlloSure
Description: Patients will receive donor-derived cell-free DNA testing for surveillance and for-cause.
Study NCT00615030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: 50 µg twice daily delivered via dry powder inhaler (DPI)
Study NCT03956394 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: UltraFast ultrasound
Description: The patient will be hospitalized by day to perform the usual follow-up of the Takayasu disease: blood sampling and Doppler ultrasound control. Then UltraFast ultrasound doppler will be assessed.
Study NCT00309855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: im and orally
Study NCT00309855 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Testosterone
Description: injections
Study NCT00309855 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Anastrazole
Description: orally x 21 days
Study NCT00309855 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dutasteride
Description: orally x 21 days
Study NCT00615030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Indacaterol
Description: Placebo matching indacaterol was delivered via SDDPI.
Study NCT00615030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Salmeterol
Description: Placebo matching salmeterol was delivered via DPI
Study NCT01786395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UF-021
Study NCT01786395 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02021903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V1: HGPO + meal and V2: placebo + meal
Description: * Ambulatory polysomnography for the night preceding each test~* Usual antiparkinsonian treatments at their usual dose and timing~* Randomisation to receive an oral solution of glucose load or a placebo (fructose). Standard meal 4 hours after the test~* During two hours following the oral solution administration and the standardized meal, we will perform the followings for each patient :~  * continuous digital blood pressure monitoring by Nexfin®~ * blood pressure monitoring at brachial artery~ * continuous polysomnographic recording~ * synchronized continuous digital audiovisual recording~ * glucose and insulin blood level monitoring Additional blood samples will be taken in order to assay the intestine-pancreatic neuropeptides including incretins GLP- 1 and GIP
Study NCT02021903 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: V1: placebo 75mg + meal and V2: HGPO 75mg + meal
Description: * Ambulatory polysomnography for the night preceding each test~* Usual antiparkinsonian treatments at their usual dose and timing~* Randomisation to receive an oral solution of glucose load or a placebo (fructose). Standard meal 4 hours after the test~* During two hours following the oral solution administration and the standardized meal, we will perform the followings for each patient :~  * continuous digital blood pressure monitoring by Nexfin®~ * blood pressure monitoring at brachial artery~ * continuous polysomnographic recording~ * synchronized continuous digital audiovisual recording~ * glucose and insulin blood level monitoring Additional blood samples will be taken in order to assay the intestine-pancreatic neuropeptides including incretins GLP- 1 and GIP
Study NCT03024190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: The technique of Kinesiotaping for spastic wrists and fingers in stroke patients is performed from the proximal interphalangeal joints of all fingers acted on the extensor carpal and digital muscle groups, with an anchor at the proximal one-third forearm.
Study NCT03136003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DDAVP
Description: The participant will take either 1 or 2 nasal sprays of IN DDAVP (known as Octostim® in Canada). After receiving IN DDAVP, the participant will rest for 30 minutes.